54 related articles for article (PubMed ID: 30790678)
1. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells.
Tome-Garcia J; Li D; Ghazaryan S; Shu L; Wu L
PLoS One; 2014; 9(6):e99525. PubMed ID: 24937171
[TBL] [Abstract][Full Text] [Related]
3. PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K/AKT/GSK-3β pathway.
Zhong J; Yuan C; Liu L; Du Y; Hui Y; Chen Z; Diao C; Yang R; Liu G; Liu X
Aging (Albany NY); 2023 Oct; 15(20):11654-11671. PubMed ID: 37899170
[TBL] [Abstract][Full Text] [Related]
4. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis.
Duan S; Moro L; Qu R; Simoneschi D; Cho H; Jiang S; Zhao H; Chang Q; de Stanchina E; Arbini AA; Pagano M
Cell Rep; 2021 Oct; 37(3):109870. PubMed ID: 34686346
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.
Muniyan S; Chou YW; Ingersoll MA; Devine A; Morris M; Odero-Marah VA; Khan SA; Chaney WG; Bu XR; Lin MF
Cancer Lett; 2014 Oct; 353(1):59-67. PubMed ID: 25050738
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z
Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532
[TBL] [Abstract][Full Text] [Related]
7. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study.
Kaur P; Shukla S; Gupta S
Carcinogenesis; 2008 Nov; 29(11):2210-7. PubMed ID: 18725386
[TBL] [Abstract][Full Text] [Related]
8. The anticancer effect of fucoidan in PC-3 prostate cancer cells.
Boo HJ; Hong JY; Kim SC; Kang JI; Kim MK; Kim EJ; Hyun JW; Koh YS; Yoo ES; Kwon JM; Kang HK
Mar Drugs; 2013 Aug; 11(8):2982-99. PubMed ID: 23966032
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells.
Robertson BW; Bonsal L; Chellaiah MA
Mol Cancer; 2010 Sep; 9():260. PubMed ID: 20868520
[TBL] [Abstract][Full Text] [Related]
10. Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway.
Yang J; Xin C; Yin G; Li J
Sci Rep; 2023 Aug; 13(1):13072. PubMed ID: 37567936
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
12. Human prostatic acid phosphatase: structure, function and regulation.
Muniyan S; Chaturvedi NK; Dwyer JG; Lagrange CA; Chaney WG; Lin MF
Int J Mol Sci; 2013 May; 14(5):10438-64. PubMed ID: 23698773
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Erk/MAPK signaling pathway is a driver for cadmium induced prostate cancer.
Dasgupta P; Kulkarni P; Bhat NS; Majid S; Shiina M; Shahryari V; Yamamura S; Tanaka Y; Gupta RK; Dahiya R; Hashimoto Y
Toxicol Appl Pharmacol; 2020 Aug; 401():115102. PubMed ID: 32512071
[TBL] [Abstract][Full Text] [Related]
14. Anillin contributes to prostate cancer progression through the regulation of IGF2BP1 to promote c-Myc and MAPK signaling.
Liu J; Wang S; Zhang C; Wei Z; Han D; Song Y; Song X; Chao F; Wu Z; Xu G; Chen G
Am J Cancer Res; 2024; 14(2):490-506. PubMed ID: 38455417
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a small-molecule NDR1 agonist for prostate cancer therapy.
Bai Y; Sui X; Xuan Z; Du Y; Fu M; Zheng Z; Yang K; Xu C; Liu Y; Liu B; Zhong M; Zhang Z; Zheng J; Hu X; Zhang L; Sun H; Shao C
Front Pharmacol; 2024; 15():1367358. PubMed ID: 38410130
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer.
Paz MFCJ; de Alencar MVOB; de Lima RMP; Sobral ALP; do Nascimento GTM; Dos Reis CA; Coêlho MDPSS; do Nascimento MLLB; Gomes Júnior AL; Machado KDC; de Menezes APM; de Lima RMT; de Oliveira Filho JWG; Dias ACS; Dos Reis AC; da Mata AMOF; Machado SA; Sousa CDC; da Silva FCC; Islam MT; de Castro E Sousa JM; Melo Cavalcante AAC
Oxid Med Cell Longev; 2020; 2020():3457890. PubMed ID: 32308801
[TBL] [Abstract][Full Text] [Related]
17. Emerging roles of ADP-dependent glucokinase in prostate cancer.
Zhang X
Mil Med Res; 2024 Feb; 11(1):15. PubMed ID: 38409104
[No Abstract] [Full Text] [Related]
18. ErbB-2 signaling in advanced prostate cancer progression and potential therapy.
Miller DR; Ingersoll MA; Lin MF
Endocr Relat Cancer; 2019 Apr; 26(4):R195-R209. PubMed ID: 31294537
[TBL] [Abstract][Full Text] [Related]
19. The impact of diurnal variation of PSA on timing of measurement in prostate biopsy.
Uzun H; Arpa M
Prostate; 2019 Oct; 79(14):1666-1672. PubMed ID: 31390085
[TBL] [Abstract][Full Text] [Related]
20. The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.
Goldberg H; Mohsin FK; Saskin R; Kulkarni GS; Berlin A; Kenk M; Wallis CJD; Chandrasekar T; Klaassen Z; Saarela O; Penn L; Alibhai SMH; Fleshner N
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):622-629. PubMed ID: 32641738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
